Nebiretic (Hydrochlorothiazide, Nebivolol)

Hydrochlorothiazide blocks sodium‑chloride reabsorption in the kidney’s distal tubule, promoting water loss and reducing blood volume. Nebivolol selectively blocks β₁‑adrenergic receptors, slowing heart rate and contractility, while also enhancing nitric‑oxide release for vasodilation. Together they provide complementary blood‑pressure‑lowering effects.

The specific dose of Nebiretic is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and other individual factors. Dosage adjustments are made according to blood‑pressure targets and tolerability.

Safety of Nebiretic in pregnancy or while breastfeeding has not been definitively established. Healthcare providers should weigh potential benefits against risks and consider alternative treatments if appropriate. Pregnant or nursing patients should discuss options with their physician.

To order Nebiretic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebiretic offers a dual mechanism by combining a thiazide diuretic and a β₁‑selective blocker, which can be more effective for patients needing both volume reduction and heart‑rate control. Compared with single‑agent therapies, it may simplify regimens but requires careful monitoring for combined side‑effects.

Nebiretic tablets should be stored at temperatures below 25 °C, in their original container, protected from moisture and direct sunlight. Keep out of reach of children and do not use if the packaging is damaged.

Nebiretic is taken orally, usually once daily with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe dehydration, marked electrolyte imbalances (especially low potassium), acute gout, significant hypotension, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience symptoms like fainting, rapid heartbeat, severe muscle pain, or swelling.

Nebiretic is contraindicated in patients with known hypersensitivity to hydrochlorothiazide, nebivolol, or any component of the formulation. It should also be avoided in individuals with severe renal impairment, uncontrolled electrolyte disturbances, or those taking certain interacting medications without close supervision.